Archive — US — techcrunch
NewLimit, founded by Coinbase CEO Brian Armstrong, raises $130M to developage-reversing treatments
NewLimit, a startup co-founded by Coinbase CEO Brian Armstrong, raised $130M to create age-reversing treatments through cellular reprogramming. The Series B funding, led by Kleiner Perkins, follows a $40M Series A. NewLimit claims progress in rejuvenating liver cells, and aims to test AI-generated drugs for potential anti-aging treatments.
Key points
- NewLimit raised $130 million in Series B funding led by Kleiner Perkins.
- The company is focused on genetically programming cells to extend healthy lifespans.
- Founded by Brian Armstrong, Blake Byers, and Jacob Kimmel, NewLimit has made strides in developing treatments to restore youthful cell characteristics.
- Byers reported three prototype medicines that can rejuvenate liver cells, restoring their ability to process fat and alcohol.
- Human trials are a few years away; in the meantime, the company utilizes AI for drug development through a simulated experimental approach.
Why it matters
- The news reflects the growing trend in biotechnology focused on longevity and anti-aging treatments.
- Other startups in the space include Retro Biosciences and Altos Labs, indicating a competitive landscape for age-related medical advancements.
- Investments in biotech focused on AI-driven pharmaceuticals are on the rise, correlating with the 2025 IT trends emphasizing AI in healthcare.
NewLimit's successful funding round highlights increasing investor interest in biotechnology aimed at prolonging healthy life, leveraging AI innovations to potentially reshape the landscape of aging therapies.